Loading organizations...
Key people at Medira Ltd.
Medira develops medical technologies focused on the treatment of structural heart diseases. The company specializes in creating solutions designed to address complex cardiovascular conditions, likely involving innovative devices or therapeutic approaches. Their work is supported by a dedicated research and development team, indicating a commitment to advancing techniques within the cardiac field.
The company was co-founded by Thomas J. Bogenschütz, who also serves as CEO, and Thomas Gut, who holds the position of Chairman. Bogenschütz brings over three decades of experience in the medical technology industry, a background that likely informed the company's foundational insight into the needs of structural heart disease patients. Medira began operations approximately five years ago, building upon the founders' extensive expertise.
Medira’s products are intended for use by medical professionals and institutions involved in cardiovascular care. The company’s long-term vision centers on enhancing treatment efficacy and improving patient outcomes for individuals suffering from structural heart conditions, contributing to progress in cardiovascular medicine.
Key people at Medira Ltd.
Medira Ltd is a now-defiant UK-based private limited company in liquidation, originally focused on medical equipment manufacturing and non-specialized wholesale trade. Incorporated in 2008, it reported approximately $7 million in revenue and around 5 employees, with activities linked to drug pipelines, patents, clinical trials, and therapeutic areas, suggesting involvement in medical or pharmaceutical supply chains.[2][1][3] The company served business services sectors but faced financial distress, entering liquidation with overdue accounts as of 31 March 2024 and confirmation statements overdue since October 2024.[3]
Medira Limited was incorporated on 19 March 2008 as a private limited company in the UK, with its registered office at 170a-172 High Street, Rayleigh, Essex, SS6 7BS.[3][5] Limited public details exist on founders or key partners, but its nature of business was classified under SIC code 46900 for non-specialized wholesale trade, evolving to include medical equipment manufacturing and business services.[2][3] Early traction appears tied to medical innovation spaces like drug pipelines and clinical trials, though no pivotal growth moments are documented before its decline into insolvency.[1]
Medira Ltd operated on the fringes of the medtech and pharmaceutical supply ecosystem, riding trends in medical equipment and wholesale distribution amid growing demand for clinical trial support and drug development tools.[1][2] Timing aligned with post-2008 expansion in UK biotech services, but market forces like supply chain disruptions and financial pressures led to its liquidation, highlighting risks for small players in non-specialized wholesale.[3][5] It had minimal broader influence, serving as a cautionary example rather than a shaper of the ecosystem.
Medira Ltd's trajectory ends in liquidation, with no active operations or revival prospects amid overdue filings. Future trends like AI-driven drug discovery or resilient medtech supply chains will bypass it, as insolvency proceedings dominate.[3] Its story underscores vulnerabilities for niche UK medwholesalers, evolving from modest revenue generator to a dissolved entity—tying back to its origins as a specialized yet fragile player in medical innovation.
